DEFA14A 1 d578334ddefa14a.htm DEFA14A DEFA14A

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

 

 

Filed by the Registrant  ☒                                 Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Pursuant to § 240.14a-12

EIGER BIOPHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

 

   No fee required.
   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

Title of each class of securities to which transaction applies:

 

     

Aggregate number of securities to which transaction applies:

 

     

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

Proposed maximum aggregate value of transaction:

 

     

Total fee paid:

 

     

   Fee paid previously with preliminary materials.
   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

Amount previously paid:

 

     

Form, Schedule or Registration Statement No:

 

     

Filing party:

 

     

Date Filed:

 

     

     

 

 

 


*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on June 12, 2018

 

LOGO

              EIGER BIOPHARMACEUTICALS,INC  

Meeting Information

 

  Meeting Type: Annual Meeting

 

  For holders as of: April 23, 2018

 

    Date: June 12, 2018                Time: 9:30 AM PDT

 

      Location: 366 Cambridge Avenue

   Palo Alto, CA 94306

    

 

    

 

 

EIGER BIOPHARMACEUTICALS, INC

350 CAMBRIDGE AVENUE, SUITE 350

PALO ALTO, CA 94306

 

 

You are receiving this communication because you hold shares in the above named company.

 

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

 

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

   

See the reverse side of this notice to obtain proxy materials and voting instructions.

 


—  Before You Vote  —

How to Access the Proxy Materials

 

  

 

Proxy Materials Available to VIEW or RECEIVE:

    
  

 

1. Form 10-K            2. Notice & Proxy Statement

    
  

 

How to View Online:

    
   Have the information that is printed in the box marked by the arrow LOGO (located on the following page) and visit: www.proxyvote.com.     
  

 

How to Request and Receive a PAPER or E-MAIL Copy:

    
   If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:     
  

1) BY INTERNET:        www.proxyvote.com

    
  

2) BY TELEPHONE:    1-800-579-1639

    
  

3) BY E-MAIL*:            sendmaterial@proxyvote.com

    
  

 

*    If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow LOGO (located on the following page) in the subject line.

    
  

 

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 29, 2018 to facilitate timely delivery.

 

    

—  How To Vote  —

Please Choose One of the Following Voting Methods

 

LOGO

   Vote In Person:    Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.     
  

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow LOGO available and follow the instructions.

    
  

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

 

    


  Voting items   
 

The Board of Directors recommends you vote

FOR both of the following nominees:

  1.   Election of Directors
      Nominees
  01   Thomas J. Dietz, Ph.D    02    Eldon Mayer
  The Board of Directors recommends you vote FOR proposal 2:
  2.   To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.
  NOTE: To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
   
            
   
   

 

LOGO